Search
Search Results
##search.searchResults.foundPlural##
-
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3551PDF: 2104HTML: 7587 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1441PDF: 1161HTML: 277 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7980PDF: 2534HTML: 2170Table 1.: 277Table 2.: 294Table 3.: 267Table 4.: 266 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3637PDF: 1480HTML: 2746 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2710PDF: 917HTML: 9076Efremov 1: 277Efremov 2: 246 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3648PDF: 2375HTML: 23648Untitled: 320Untitled: 297Untitled: 313 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
2120PDF: 870HTML: 657 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1532PDF: 875HTML: 1042 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2752PDF: 1743HTML: 2465Table1: 285 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4775PDF: 1752HTML: 4348Tables and Images: 298 -
VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS
3983PDF: 1690HTML: 8262Randi Fig: 235 -
MAGNUSIOMYCES CAPITATUS BREAKTHROUGH INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RECEIVING ECHINOCANDIN PROPHYLAXIS: CLINICAL FEATURES, MANAGEMENT, AND REVIEW OF THE LITERATURE
153PDF: 224Suppl. Files: 42Html: 121Html Suppl. Files: 109 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1631PDF: 995Suppl. Files: 497HTML: 306 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
3076PDF: 1461HTML: 3743Untitled: 260Untitled: 262Untitled: 220 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2149PDF: 2034HTML: 813 -
Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma
1731PDF: 836HTML: 4431Figure 1: 199Untitled: 188Untitled: 246 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
1101PDF: 592HTML: 349 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
2499PDF: 810HTML: 2159Untitled: 288Untitled: 200Untitled: 233Untitled: 212Untitled: 228Untitled: 248Untitled: 235 -
NF- ?B Essential Modulator Deficiency Leading to Disseminated Cutaneous Atypical Mycobacteria
2312PDF: 1190HTML: 10770Untitled: 243 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3662PDF: 1375HTML: 2416Fi.1 Gritti.Rambaldi: 263 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1766PDF: 1153HTML: 511 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2526PDF: 1085HTML: 1677Fig 1: 263Tab I: 262Cover Letter: 269 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4151PDF: 1137HTML: 3917Untitled: 205Cneo. Fig.1: 147Untitled: 138Untitled: 172Untitled: 175







